Company news

Citius Pharmaceuticals, Inc. news in 2025

Citius Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

December 23, 2025

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

December 23, 2025

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

December 10, 2025

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

December 8, 2025

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

December 3, 2025

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

November 30, 2025

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

November 25, 2025

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

November 21, 2025

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

October 21, 2025

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

October 21, 2025

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

October 19, 2025

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

October 17, 2025

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

October 16, 2025

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

September 10, 2025

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

September 8, 2025

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

August 22, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

Citius Oncology Announces Closing of $9.0 Million Public Offering

July 16, 2025

Citius Oncology Announces Pricing of $9.0 Million Public Offering

July 16, 2025

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

July 15, 2025

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 8, 2025

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

June 17, 2025

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

June 12, 2025

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

June 10, 2025

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

June 9, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 5, 2025

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

April 1, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

February 13, 2025

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

January 7, 2025

Decks in 2025